

Annex 2

WHO good manufacturing practices for active pharmaceutical ingredients

1. **Introduction**
 - 1.1 Objective
 - 1.2 Regulatory applicability
 - 1.3 Scope
2. **Quality management**
 - 2.1 Principles
 - 2.2 Responsibilities of the quality unit(s)
 - 2.3 Responsibility for production activities
 - 2.4 Internal audits (self-inspection)
 - 2.5 Product quality review
3. **Personnel**
 - 3.1 Personnel qualifications
 - 3.2 Personnel hygiene
 - 3.3 Consultants
4. **Buildings and facilities**
 - 4.1 Design and construction
 - 4.2 Utilities
 - 4.3 Water
 - 4.4 Containment
 - 4.5 Lighting
 - 4.6 Sewage and refuse
 - 4.7 Sanitation and maintenance
5. **Process equipment**
 - 5.1 Design and construction
 - 5.2 Equipment maintenance and cleaning
 - 5.3 Calibration
 - 5.4 Computerized systems
6. **Documentation and records**
 - 6.1 Documentation system and specifications
 - 6.2 Equipment cleaning and use record
 - 6.3 Records of raw materials, intermediates, API labelling and packaging materials
 - 6.4 Master production instructions (master production and control records)
 - 6.5 Batch production records (batch production and control records)
 - 6.6 Laboratory control records

- 6.7 Batch production record review
- 7. Materials management**
 - 7.1 General controls
 - 7.2 Receipt and quarantine
 - 7.3 Sampling and testing of incoming production materials
 - 7.4 Storage
 - 7.5 Re-evaluation
- 8. Production and in-process controls**
 - 8.1 Production operations
 - 8.2 Time limits
 - 8.3 In-process sampling and controls
 - 8.4 Blending batches of intermediates or APIs
 - 8.5 Contamination control
- 9. Packaging and identification labelling of APIs and intermediates**
 - 9.1 General
 - 9.2 Packaging materials
 - 9.3 Label issuance and control
 - 9.4 Packaging and labelling operations
- 10. Storage and distribution**
 - 10.1 Warehousing procedures
 - 10.2 Distribution procedures
- 11. Laboratory controls**
 - 11.1 General controls
 - 11.2 Testing of intermediates and APIs
 - 11.3 Validation of analytical procedures
 - 11.4 Certificates of analysis
 - 11.5 Stability monitoring of APIs
 - 11.6 Expiry and retest dating
 - 11.7 Reserve/retention samples
- 12. Validation**
 - 12.1 Validation policy
 - 12.2 Validation documentation
 - 12.3 Qualification
 - 12.4 Approaches to process validation
 - 12.5 Process validation programme
 - 12.6 Periodic review of validated systems
 - 12.7 Cleaning validation
 - 12.8 Validation of analytical methods
- 13. Change control**
- 14. Rejection and reuse of materials**
 - 14.1 Rejection
 - 14.2 Reprocessing
 - 14.3 Reworking
 - 14.4 Recovery of materials and solvents

- 14.5 Returns
- 15. Complaints and recalls
- 16. Contract manufacturers (including laboratories)
- 17. Agents, brokers, traders, distributors, repackers and relabellers
 - 17.1 Applicability
 - 17.2 Traceability of distributed APIs and intermediates
 - 17.3 Quality management
 - 17.4 Repackaging, relabelling and holding of APIs and intermediates
 - 17.5 Stability
 - 17.6 Transfer of information
 - 17.7 Handling of complaints and recalls
 - 17.8 Handling of returns
- 18. Specific guidance for APIs manufactured by cell culture/fermentation
 - 18.1 General
 - 18.2 Cell bank maintenance and record keeping
 - 18.3 Cell culture/fermentation
 - 18.4 Harvesting, isolation and purification
 - 18.5 Viral removal/inactivation steps
- 19. APIs for use in clinical trials
 - 19.1 General
 - 19.2 Quality
 - 19.3 Equipment and facilities
 - 19.4 Control of raw materials
 - 19.5 Production
 - 19.6 Validation
 - 19.7 Changes
 - 19.8 Laboratory controls
 - 19.9 Documentation
- 20. Glossary

References

Appendix 1

List of references for related WHO guidelines

Appendix 2

General notes: additional clarifications and explanations

This text is based on the International Conference on Harmonisation (ICH) Q7: *Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients*. November 2000.

1. Introduction

1.1 Objective

This document (guide) is intended to provide guidance regarding good manufacturing practices (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) under an appropriate system for managing quality. It is also intended to help ensure that APIs meet the requirements for quality and purity that they purport or are represented to possess.

In this guide “manufacturing” is defined to include all operations of receipt of materials, production, packaging, repackaging, labelling, relabelling, quality control, release, storage and distribution of APIs and the related controls. In this guide the term “should” indicates recommendations that are expected to apply unless shown to be inapplicable or replaced by an alternative demonstrated to provide at least an equivalent level of quality assurance. For the purposes of this guide, the terms “current good manufacturing practices” and “good manufacturing practices” are equivalent.

The guide as a whole does not cover safety aspects for the personnel engaged in the manufacture, nor aspects of protection of the environment. These controls are inherent responsibilities of the manufacturer and are governed by national laws.

This guide is not intended to define registration and filing requirements or modify pharmacopoeial requirements. This guide does not affect the ability of the responsible regulatory agency to establish specific registration or filing requirements regarding APIs within the context of marketing or manufacturing authorizations or pharmaceutical applications. All commitments in registration and filing documents must be met.

1.2 Regulatory applicability

Within the world community, materials may vary as to the legal classification as an API. When a material is classified as an API in the region or country in which it is manufactured or used in a pharmaceutical product, it should be manufactured according to this guide.

1.3 Scope

This guide applies to the manufacture of APIs for use in finished pharmaceutical products (FPPs). It applies to the manufacture of sterile APIs only up to the point immediately prior to the APIs being rendered sterile. The sterilization and aseptic processing of sterile APIs are not covered by this guidance, but should be performed in accordance with GMP guidelines for FPPs as defined by local authorities.

This guide covers APIs that are manufactured by chemical synthesis, extraction, cell culture or fermentation, by recovery from natural sources, or by any combination of these processes.

Specific guidance for APIs manufactured by cell culture or fermentation is described in section 18.

This guide excludes all vaccines, whole cells, whole blood and plasma, blood and plasma derivatives (plasma fractionation), and gene therapy APIs. However, it does include APIs that are produced using blood or plasma as raw materials. Note that cell substrates (mammalian, plant, insect or microbial cells, tissue or animal sources including transgenic animals) and early process steps may be subject to GMP but are not covered by this guide. In addition, the guide does not apply to medical gases, bulk-packaged FPPs, and manufacturing and control aspects specific to radiopharmaceuticals.

Section 19 contains guidance that only applies to the manufacture of APIs used in the production of FPPs specifically for clinical trials (investigational medicinal products).

An “API starting material” is a raw material, intermediate, or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API starting material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement, or produced in house.

API starting materials normally have defined chemical properties and structure. The company should designate and document the rationale for the point at which production of the API begins. For synthetic processes, this is known as the point at which “API starting materials” are entered into the process. For other processes (e.g. fermentation, extraction or purification), this rationale should be established on a case-by-case basis.

Table 1 gives guidance on the point at which the API starting material is normally introduced into the process. From this point on, appropriate GMP as defined in this guide should be applied to these intermediate and/or API manufacturing steps. This would include the validation of critical process steps determined to impact the quality of the API. However, it should be noted that the fact that a company chooses to validate a process step does not necessarily define that step as critical.

The guidance in this document would normally be applied to the steps shown in grey in Table 1. It does not imply that all steps shown should be completed. The stringency of GMP in API manufacturing should increase as the process proceeds from early API steps to final steps, purification and packaging. Physical processing of APIs, such as granulation, coating

or physical manipulation of particle size (e.g. milling and micronizing), should be conducted at least to the standards of this guide.

This GMP guide does not apply to steps prior to the introduction of the defined “API starting material”.

Table 1^a

Application of this guide to API manufacturing

Type of manufacturing	Application of this guide to steps (shown in grey) used in this type of manufacturing				
Chemical manufacturing	Production of the API starting material	Introduction of the API starting material into process	Production of intermediate(s)	Isolation and purification	Physical processing, and packaging
API derived from animal sources	Collection of organ, fluid, or tissue	Cutting, mixing, and/or initial processing	Introduction of the API starting material into process	Isolation and purification	Physical processing, and packaging
API extracted from plant sources	Collection of plants	Cutting and initial extraction(s)	Introduction of the API starting material into process	Isolation and purification	Physical processing, and packaging
Herbal extracts used as API	Collection of plants	Cutting and initial extraction		Further extraction	Physical processing, and packaging
API consisting of comminuted or powdered herbs	Collection of plants and/or cultivation and harvesting	Cutting/ comminuting			Physical processing, and packaging
Biotechnology: fermentation/ cell culture	Establishment of master cell bank and working cell bank	Maintenance of working cell bank	Cell culture and/or fermentation	Isolation and purification	Physical processing, and packaging
“Classical” fermentation to produce an API	Establishment of cell bank	Maintenance of the cell bank	Introduction of the cells into fermentation	Isolation and purification	Physical processing, and packaging

^a This table has been taken from the ICH Harmonised Tripartite Guideline: Active Pharmaceutical Ingredients Q7. Current *Step 4* version, dated 10 November 2000.



2. **Quality management**

2.1 **Principles¹**

2.10 Quality should be the responsibility of all persons involved in manufacturing.

2.11 Each manufacturer should establish, document and implement an effective system for managing quality that involves the active participation of management and appropriate manufacturing personnel.

2.12 The system for managing quality should encompass the organizational structure, procedures, processes and resources, as well as activities necessary to ensure confidence that the API will meet its intended specifications for quality and purity. All quality-related activities should be defined and documented.

2.13 There should be a quality unit(s) that is independent of production and that fulfils both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.

2.14 The persons authorized to release intermediates and APIs should be specified.

2.15 All quality-related activities should be recorded at the time they are performed.

2.16 Any deviation from established procedures should be documented and explained. Critical deviations should be investigated, and the investigation and its conclusions should be documented.

2.17 No materials should be released or used before the satisfactory completion of evaluation by the quality unit(s) unless there are appropriate systems in place to allow for such use (e.g. release under quarantine as described in section 10.20 or the use of raw materials or intermediates pending completion of evaluation).

2.18 Procedures should exist for notifying responsible management in a timely manner of regulatory inspections, serious GMP deficiencies, product defects and related actions (e.g. quality related complaints, recalls and regulatory actions).

2.2 **Responsibilities of the quality unit(s)**

2.20 The quality unit(s) should be involved in all quality-related matters.

¹ This system of numbering sections is different to the usual WHO style. It is used here to harmonize with the guide used in inspection reports internationally.

2.21 The quality unit(s) should review and approve all appropriate quality-related documents.

2.22 The main responsibilities of the independent quality unit(s) should not be delegated.

These responsibilities should be described in writing and should include but not necessarily be limited to:

1. Releasing or rejecting all APIs. Releasing or rejecting intermediates for use outside the control of the manufacturing company.
2. Establishing a system to release or reject raw materials, intermediates, packaging and labelling materials.
3. Reviewing completed batch production and laboratory control records of critical process steps before release of the API for distribution.
4. Making sure that critical deviations are investigated and resolved.
5. Approving all specifications and master production instructions.
6. Approving all procedures impacting the quality of intermediates or APIs.
7. Making sure that internal audits (self-inspections) are performed.
8. Approving intermediate and API contract manufacturers.
9. Approving changes that potentially impact quality of intermediates or APIs.
10. Reviewing and approving validation protocols and reports.
11. Making sure that quality-related complaints are investigated and resolved.
12. Making sure that effective systems are used for maintaining and calibrating critical equipment.
13. Making sure that materials are appropriately tested and the results are reported.
14. Making sure that there are stability data to support retest or expiry dates and storage conditions on APIs and/or intermediates where appropriate.
15. Performing product quality reviews (as defined in section 2.5).

2.3 **Responsibility for production activities**

The responsibility for production activities should be described in writing, and should include but not necessarily be limited to:

1. Preparing, reviewing, approving and distributing the instructions for the production of intermediates or APIs according to written procedures.
2. Producing APIs and, when appropriate, intermediates according to pre-approved instructions.
3. Reviewing all production batch records and ensuring that these are completed and signed.

4. Making sure that all production deviations are reported and evaluated and that critical deviations are investigated and the conclusions are recorded.
5. Making sure that production facilities are clean and when appropriate disinfected.
6. Making sure that the necessary calibrations are performed and records kept.
7. Making sure that the premises and equipment are maintained and records kept.
8. Making sure that validation protocols and reports are reviewed and approved.
9. Evaluating proposed changes in product, process or equipment.
10. Making sure that new and, when appropriate, modified facilities and equipment are qualified.

2.4 **Internal audits (self-inspection)**

2.40 In order to verify compliance with the principles of GMP for APIs, regular internal audits should be performed in accordance with an approved schedule.

2.41 Audit findings and corrective actions should be documented and brought to the attention of the responsible management of the firm. Agreed corrective actions should be completed in a timely and effective manner.

2.5 **Product quality review**

2.50 Regular quality reviews of APIs should be conducted with the objective of verifying the consistency of the process. Such reviews should normally be conducted and documented annually and should include at least a review of:

- critical in-process control and critical API test results;
- all batches that failed to meet established specification(s);
- all critical deviations or non-conformances and related investigations;
- any changes carried out to the processes or analytical methods;
- results of the stability monitoring programme;
- quality-related returns, complaints and recalls; and
- adequacy of corrective actions.

2.51 The results of this review should be evaluated and an assessment made of whether corrective action or any revalidation should be undertaken. Reasons for such corrective action should be documented. Agreed corrective actions should be completed in a timely and effective manner.

3. Personnel

3.1 Personnel qualifications

3.10 There should be an adequate number of personnel qualified by appropriate education, training and/or experience to perform and supervise the manufacture of intermediates and APIs.

3.11 The responsibilities of all personnel engaged in the manufacture of intermediates and APIs should be specified in writing.

3.12 Training should be regularly conducted by qualified individuals and should cover, at a minimum, the particular operations that the employee performs, and GMP as it relates to the employee's functions. Records of training should be maintained. Training should be periodically assessed.

3.2 Personnel hygiene

3.20 Personnel should practice good sanitation and health habits.

3.21 Personnel should wear clean clothing suitable for the manufacturing activity with which they are involved and this clothing should be changed when appropriate. Additional protective apparel, such as head, face, hand and arm coverings, should be worn when necessary, to protect intermediates and APIs from contamination.

3.22 Personnel should avoid direct contact with intermediates or APIs.

3.23 Smoking, eating, drinking, chewing and the storage of food should be restricted to certain designated areas separate from the manufacturing areas.

3.24 Personnel with an infectious disease or who have open lesions on the exposed surface of the body should not engage in activities that could result in compromising the quality of APIs. Any person shown at any time (either by medical examination or supervisory observation) to have an apparent illness or open lesions should be excluded from activities where their health condition could adversely affect the quality of the APIs, until the condition is corrected or qualified medical personnel determine that the person's inclusion would not jeopardize the safety or quality of the APIs.

3.3 Consultants

3.30 Consultants advising on the manufacture and control of intermediates or APIs should have sufficient education, training, and experience, or any combination thereof, to advise on the subject for which they are retained.

3.31 Records should be maintained stating the name, address, qualifications and type of service provided by these consultants.

4. Buildings and facilities

4.1 Design and construction

4.10 Buildings and facilities used in the manufacture of intermediates and APIs should be located, designed, and constructed to facilitate cleaning, maintenance and operations as appropriate to the type and stage of manufacture. Facilities should also be designed to minimize potential contamination. Where microbiological specifications have been established for the intermediate or API, facilities should also be designed to limit exposure to objectionable microbiological contaminants as appropriate.

4.11 Buildings and facilities should have adequate space for the orderly placement of equipment and materials to prevent mix-ups and contamination.

4.12 Where the equipment itself (e.g. closed or contained systems) provides adequate protection of the material, such equipment can be located outdoors.

4.13 The flow of materials and personnel through the building or facilities should be designed to prevent mix-ups or contamination.

4.14 There should be defined areas or other control systems for the following activities:

- receipt, identification, sampling, and quarantine of incoming materials, pending release or rejection;
- quarantine before release or rejection of intermediates and APIs;
- sampling of intermediates and APIs;
- holding rejected materials before further disposition (e.g. return, reprocessing or destruction);
- storage of released materials;
- production operations;
- packaging and labelling operations; and
- laboratory operations.

4.15 Adequate, clean washing and toilet facilities should be provided for personnel. These washing facilities should be equipped with hot and cold water as appropriate, soap or detergent, air driers or single-use towels. The washing and toilet facilities should be separate from, but easily accessible to, manufacturing areas. Adequate facilities for showering and/or changing clothes should be provided, when appropriate.

4.16 Laboratory areas and operations should normally be separated from production areas. Some laboratory areas, in particular those used for in-process controls, can be located in production areas, provided the operations of the production process do not adversely affect the accuracy of the laboratory measurements, and the laboratory and its operations do not adversely affect the production process or intermediate or API.

4.2 Utilities

4.20 All utilities that could impact on product quality (e.g. steam, gases, compressed air, and heating, ventilation and air conditioning) should be qualified and appropriately monitored and action should be taken when limits are exceeded. Drawings for these utility systems should be available.

4.21 Adequate ventilation, air filtration and exhaust systems should be provided, where appropriate. These systems should be designed and constructed to minimize risks of contamination and cross-contamination and should include equipment for control of air pressure, microorganisms (if appropriate), dust, humidity, and temperature, as appropriate to the stage of manufacture. Particular attention should be given to areas where APIs are exposed to the environment.

4.22 If air is recirculated to production areas, appropriate measures should be taken to control risks of contamination and cross-contamination.

4.23 Permanently installed pipework should be appropriately identified. This can be accomplished by identifying individual lines, documentation, computer control systems, or alternative means. Pipework should be located to avoid risks of contamination of the intermediate or API.

4.24 Drains should be of adequate size and should be provided with an air break or a suitable device to prevent back-siphonage, when appropriate.

4.3 Water

4.30 Water used in the manufacture of APIs should be demonstrated to be suitable for its intended use.

4.31 Unless otherwise justified, process water should, at a minimum, meet WHO guidelines for drinking (potable) water quality.

4.32 If drinking (potable) water is insufficient to assure API quality, and tighter chemical and/or microbiological water quality specifications are called for, appropriate specifications for physical and chemical attributes, total microbial counts, objectionable organisms and/or endotoxins should be established.

4.33 Where water used in the process is treated by the manufacturer to achieve a defined quality, the treatment process should be validated and monitored with appropriate action limits.

4.34 Where the manufacturer of a non-sterile API either intends or claims that it is suitable for use in further processing to produce a sterile FPP, water used in the final isolation and purification steps should be monitored and controlled for total microbial counts, objectionable organisms and endotoxins.

4.4 **Containment**

4.40 Dedicated production areas, which can include facilities, air handling equipment and/or process equipment, should be employed in the production of highly sensitizing materials, such as penicillins or cephalosporins.

4.41 Dedicated production areas should also be considered when material of an infectious nature or high pharmacological activity or toxicity is involved (e.g. certain steroids or cytotoxic anti-cancer agents) unless validated inactivation and/or cleaning procedures are established and maintained.

4.42 Appropriate measures should be established and implemented to prevent cross-contamination, e.g. from personnel or materials, moving from one dedicated area to another.

4.43 Any production activities (including weighing, milling or packaging) of highly toxic non-pharmaceutical materials such as herbicides and pesticides should not be conducted using the buildings and/or equipment being used for the production of APIs. Handling and storage of these highly toxic non-pharmaceutical materials should be separate from APIs.

4.5 **Lighting**

4.50 Adequate lighting should be provided in all areas to facilitate cleaning, maintenance and proper operations.

4.6 **Sewage and refuse**

4.60 Sewage, refuse and other waste (e.g. solids, liquids, or gaseous by-products from manufacturing) in and from buildings and the immediate surrounding area should be disposed of in a safe, timely and sanitary manner. Containers and/or pipes for waste material should be clearly identified.

4.7 **Sanitation and maintenance**

4.70 Buildings used in the manufacture of intermediates and APIs should be properly maintained and repaired and kept in a clean condition.

4.71 Written procedures should be established assigning responsibility for sanitation and describing the cleaning schedules, methods, equipment and materials to be used in cleaning buildings and facilities.

4.72 When necessary, written procedures should also be established for the use of suitable rodenticides, insecticides, fungicides, fumigating agents and cleaning and sanitizing agents to prevent the contamination of equipment, raw materials, packaging or labelling materials, intermediates and APIs.

5. **Process equipment**

5.1 **Design and construction**

5.10 Equipment used in the manufacture of intermediates and APIs should be of appropriate design and adequate size, and suitably located for its intended use, cleaning, sanitization (where appropriate) and maintenance.

5.11 Equipment should be constructed so that surfaces that contact raw materials, intermediates or APIs do not alter the quality of the intermediates and APIs beyond the official or other established specifications.

5.12 Production equipment should only be used within its qualified operating range.

5.13 Major equipment (e.g. reactors, storage containers) and permanently installed processing lines used during the production of an intermediate or API should be appropriately identified.

5.14 Any substances associated with the operation of equipment, such as lubricants, heating fluids or coolants, should not contact intermediates or APIs so as to alter their quality beyond the official or other established specifications. Any deviations from this should be evaluated to ensure that there are no detrimental effects upon the fitness for purpose of the material. Wherever possible, food-grade lubricants and oils should be used.

5.15 Closed or contained equipment should be used whenever appropriate. Where open equipment is used, or equipment is opened, appropriate precautions should be taken to minimize the risk of contamination.

5.16 A set of current drawings should be maintained for equipment and critical installations (e.g. instrumentation and utility systems).

5.2 **Equipment maintenance and cleaning**

5.20 Schedules and procedures (including assignment of responsibility) should be established for the preventive maintenance of equipment.

5.21 Written procedures should be established for cleaning of equipment and its subsequent release for use in the manufacture of intermediates and APIs. Cleaning procedures should contain sufficient details to enable operators to clean each type of equipment in a reproducible and effective manner. These procedures should include:

- assignment of responsibility for cleaning of equipment;
- cleaning schedules, including, where appropriate, sanitizing schedules;
- a complete description of the methods and materials, including dilution of cleaning agents used to clean equipment;

- when appropriate, instructions for disassembling and reassembling each article of equipment to ensure proper cleaning;
- instructions for the removal or obliteration of previous batch identification;
- instructions for the protection of clean equipment from contamination prior to use;
- inspection of equipment for cleanliness immediately before use, if practical; and
- establishing the maximum time that may elapse between the completion of processing and equipment cleaning, when appropriate.

5.22 Equipment and utensils should be cleaned, stored and, where appropriate, sanitized or sterilized to prevent contamination or carry-over of a material that would alter the quality of the intermediate or API beyond the official or other established specifications.

5.23 Where equipment is assigned to continuous production or campaign production of successive batches of the same intermediate or API, this equipment should be cleaned at appropriate intervals to prevent build-up and carry-over of contaminants (e.g. degradants or objectionable levels of microorganisms).

5.24 Non-dedicated equipment should be cleaned between production of different materials to prevent cross-contamination.

5.25 Acceptance criteria for residues and the choice of cleaning procedures and cleaning agents should be defined and justified.

5.26 Equipment should be identified as to its contents and its cleanliness status by appropriate means.

5.3 Calibration

5.30 Control, weighing, measuring, monitoring and test equipment that is critical for assuring the quality of intermediates or APIs should be calibrated according to written procedures and an established schedule.

5.31 Equipment calibrations should be performed using standards traceable to certified standards, if these exist.

5.32 Records of these calibrations should be maintained.

5.33 The current calibration status of critical equipment should be known and verifiable.

5.34 Instruments that do not meet calibration criteria should not be used.

5.35 Deviations from approved standards of calibration on critical instruments should be investigated to determine if these could have had an

impact on the quality of the intermediate(s) or API(s) manufactured using this equipment since the last successful calibration.

5.4 **Computerized systems**

5.40 GMP-related computerized systems should be validated. The depth and scope of validation depends on the diversity, complexity and criticality of the computerized application.

5.41 Appropriate installation qualification and operational qualification should demonstrate the suitability of computer hardware and software to perform assigned tasks.

5.42 Commercially available software that has been qualified does not require the same level of testing. If an existing system was not validated at the time of installation, a retrospective validation could be conducted if appropriate documentation is available.

5.43 Computerized systems should have sufficient controls to prevent unauthorized access or changes to data. There should be controls to prevent omissions in data (e.g the system being turned off and data not captured). There should be a record of any data change made, the previous entry, the person who made the change and when the change was made.

5.44 Written procedures should be available for the operation and maintenance of computerized systems.

5.45 Where critical data are being entered manually, there should be an additional check on the accuracy of the data entered. This can be done by a second operator or by the system itself.

5.46 Incidents related to computerized systems that could affect the quality of intermediates or APIs or the reliability of records or test results should be recorded and investigated.

5.47 Changes to the computerized system should be made according to a change procedure and should be formally authorized, documented and tested. Records should be kept of all changes, including modifications and enhancements made to the hardware, software and any other critical component of the system. These records should demonstrate that the system is maintained in a validated state.

5.48 If system breakdowns or failures will result in the permanent loss of records, a back-up system should be provided. A means of ensuring data protection should be established for all computerized systems.

5.49 Data can be recorded by a second means in addition to the computer system.

6. Documentation and records

6.1 Documentation system and specifications

6.10 All documents related to the manufacture of intermediates or APIs should be prepared, reviewed, approved and distributed according to written procedures. Such documents can be in paper or electronic form.

6.11 The issuance, revision, superseding and withdrawal of all documents should be controlled with maintenance of revision histories.

6.12 A procedure should be established for retaining all appropriate documents (e.g. development history reports, scale-up reports, technical transfer reports, process validation reports, training records, production records, control records and distribution records). The retention periods for these documents should be specified.

6.13 All production, control and distribution records should be retained for at least one year after the expiry date of the batch. For APIs with retest dates, records should be retained for at least three years after the batch is completely distributed.

6.14 Entries in records should be made indelibly in spaces provided for such entries, directly after performing the activities, and should identify the person making the entry. Corrections to entries should be dated and signed ensuring that the original entry remains readable.

6.15 During the retention period, originals or copies of records should be readily available at the establishment where the activities described in these records occurred. Records that can be promptly retrieved from another location by electronic or other means are acceptable.

6.16 Specifications, instructions, procedures and records can be retained either as originals or as true copies such as photocopies, microfilm, microfiche, or other accurate reproductions of the original records. Where reduction techniques such as microfilming or electronic records are used, suitable retrieval equipment and a means to produce a hard copy should be readily available.

6.17 Specifications should be established and documented for raw materials, intermediates where necessary, APIs and labelling and packaging materials. In addition, specifications may be appropriate for certain other materials, such as process aids, gaskets or other materials used during the production of intermediates or APIs that could critically impact on quality. Acceptance criteria should be established and documented for in-process controls.

6.18 If electronic signatures are used on documents they should be authenticated and secure.

6.2 **Equipment cleaning and use record**

6.20 Records of major equipment use, cleaning, sanitization and/or sterilization and maintenance should show the date, time (if appropriate), product and batch number of each batch processed in the equipment, and the person who performed the cleaning and maintenance.

6.21 If equipment is dedicated to manufacturing one intermediate or API, then individual equipment records are not necessary if batches of the intermediate or API follow in traceable sequence. In cases where dedicated equipment is employed, the records of cleaning, maintenance and use can be part of the batch record or maintained separately.

6.3 **Records of raw materials, intermediates, API labelling and packaging materials**

6.30 Records of raw materials, intermediates, API labelling and packaging materials should be maintained including:

- the name of the manufacturer, identity and quantity of each shipment of each batch of raw materials, intermediates or labelling and packaging materials for APIs; the name of the supplier; the supplier's control number(s), if known, or other identification number; the number allocated on receipt; and the date of receipt;
- the results of any test or examination performed and the conclusions derived from this;
- records tracing the use of materials;
- documentation of the examination and review of API labelling and packaging material for conformity with established specifications; and
- the final decision regarding rejected raw materials, intermediates or API labelling and packaging materials.

6.31 Master (approved) labels should be maintained for comparison to issued labels.

6.4 **Master production instructions (master production and control records)**

6.40 To ensure uniformity from batch to batch, master production instructions for each intermediate and API should be prepared, dated and signed by one person and independently checked, dated and signed by a person in the quality unit(s).

6.41 Master production instructions should include:

- the name of the intermediate or API being manufactured and an identifying document reference code, if applicable;

- a complete list of raw materials and intermediates designated by names or codes sufficiently specific to identify any special quality characteristics;
- an accurate statement of the quantity or ratio of each raw material or intermediate to be used, including the unit of measure. Where the quantity is not fixed, the calculation for each batch size or rate of production should be included. Variations to quantities should be included where they are justified;
- the production location and major production equipment to be used;
- detailed production instructions, including the:
 - sequences to be followed,
 - ranges of process parameters to be used,
 - sampling instructions and in-process controls with their acceptance criteria, where appropriate,
 - time limits for completion of individual processing steps and/or the total process, where appropriate, and
 - expected yield ranges at appropriate phases of processing or time;
- where appropriate, special notations and precautions to be followed, or cross-references to these; and
- the instructions for storage of the intermediate or API to assure its suitability for use, including the labelling and packaging materials and special storage conditions with time limits, where appropriate.

6.5 **Batch production records (batch production and control records)**

6.50 Batch production records should be prepared for each intermediate and API and should include complete information relating to the production and control of each batch. The batch production record should be checked before issuance to assure that it is the correct version and is a legible accurate reproduction of the appropriate master production instruction. If the batch production record is produced from a separate part of the master document, that document should include a reference to the current master production instruction being used.

6.51 These records should be numbered with a unique batch or identification number, dated and signed when issued. In continuous production, the product code, together with the date and time, can serve as the unique identifier until the final number is allocated.

6.52 Documentation of completion of each significant step in the batch production records (batch production and control records) should include:

- dates and, when appropriate, times;
- identity of major equipment (e.g., reactors, driers and mills) used;

- specific identification of each batch, including weights, measures, and batch numbers of raw materials, intermediates, or any reprocessed materials used during manufacturing;
- actual results recorded for critical process parameters;
- any sampling performed;
- signatures of the persons performing and directly supervising or checking each critical step in the operation;
- in-process and laboratory test results;
- actual yield at appropriate phases or times;
- description of packaging and label for intermediate or API;
- representative label of API or intermediate if made commercially available;
- any deviation noted, its evaluation, investigation conducted (if appropriate) or reference to that investigation if stored separately; and
- results of release testing.

6.53 Written procedures should be established and followed for investigating critical deviations or the failure of a batch of intermediate or API to meet specifications. The investigation should extend to other batches that may have been associated with the specific failure or deviation.

6.6 Laboratory control records

6.60 Laboratory control records should include complete data derived from all tests conducted to ensure compliance with established specifications and standards, including examinations and assays, as follows:

- a description of samples received for testing, including the name of the material or its source, batch number or other distinctive code, the date the sample was taken and, where appropriate, the quantity and date the sample was received for testing;
- a statement of or reference to each test method used;
- a statement of the weight or measure of sample used for each test as described by the method;
- data on or cross-reference to the preparation and testing of reference standards, reagents and standard solutions;
- a complete record of all raw data generated during each test, in addition to graphs, charts and spectra from laboratory instrumentation, properly identified to show the specific material and batch tested;
- a record of all calculations performed in connection with the test, including, for example, units of measure, conversion factors and equivalency factors;
- a statement of the test results and how they compare with established acceptance criteria;

- the signature of the person who performed each test and the date(s) the tests were performed; and
- the date and signature of a second person showing that the original records have been reviewed for accuracy, completeness and compliance with established standards.

6.61 Complete records should also be maintained for:

- any modifications to an established analytical method;
- periodic calibration of laboratory instruments, apparatus, gauges and recording devices;
- all stability testing performed on APIs; and
- out-of-specification (OOS) investigations.

6.7 Batch production record review

6.70 Written procedures should be established and followed for the review and approval of batch production and laboratory control records, including packaging and labelling, to determine compliance of the intermediate or API with established specifications before a batch is released or distributed.

6.71 Batch production and laboratory control records of critical process steps should be reviewed and approved by the quality unit(s) before an API batch is released or distributed. Production and laboratory control records of non-critical process steps can be reviewed by qualified production personnel or other units following procedures approved by the quality unit(s).

6.72 All deviation, investigation and OOS reports should be reviewed as part of the batch record review before the batch is released.

6.73 The quality unit(s) can delegate to the production unit the responsibility and authority for release of intermediates, except for those shipped outside the control of the manufacturing company.

7. Materials management

7.1 General controls

7.10 There should be written procedures describing the receipt, identification, quarantine, storage, handling, sampling, testing and approval or rejection of materials.

7.11 Manufacturers of intermediates and/or APIs should have a system for evaluating the suppliers of critical materials.

7.12 Materials should be purchased against an agreed specification, from a supplier or suppliers approved by the quality unit(s).

7.13 If the supplier of a critical material is not the manufacturer of that material, the name and address of that manufacturer should be known to the intermediate and/or API manufacturer.

7.14 Changing the source of supply of critical raw materials should be done according to section 13, Change control.

7.2 Receipt and quarantine

7.20 Upon receipt and before acceptance, each container or grouping of containers of materials should be examined visually for correct labelling (including correlation between the name used by the supplier and the in-house name, if these are different), damage to containers, broken seals and evidence of tampering or contamination. Materials should be held under quarantine until they have been sampled, examined or tested as appropriate, and then released for use.

7.21 Before incoming materials are mixed with existing stocks (e.g. solvents or stocks in silos), they should be identified as correct, tested, if appropriate, and released. Procedures should be available to prevent discharging incoming materials wrongly into the existing stock.

7.22 If bulk deliveries are made in non-dedicated tankers, there should be assurance of no cross-contamination from the tanker. Means of providing this assurance could include one or more of the following:

- certificate of cleaning;
- testing for trace impurities;
- audit of the supplier.

7.23 Large storage containers, and their attendant manifolds, filling and discharge lines should be appropriately identified.

7.24 Each container or grouping of containers (batches) of materials should be assigned and identified with a distinctive code, batch or receipt number. This number should be used in recording the disposition of each batch. A system should be in place to identify the status of each batch.

7.3 Sampling and testing of incoming production materials

7.30 At least one test to verify the identity of each batch of material should be conducted, with the exception of the materials described below in section 7.32. A supplier's certificate of analysis can be used in place of performing other tests, provided that the manufacturer has a system in place to evaluate suppliers.

7.31 Supplier approval should include an evaluation that provides adequate evidence (e.g. past quality history) that the manufacturer can consistently

provide material meeting specifications. Full analyses should be conducted on at least three batches before reducing in-house testing. However, as a minimum, a full analysis should be performed at appropriate intervals and compared with the certificates of analysis. Reliability of certificates of analysis should be checked at regular intervals.

7.32 Processing aids, hazardous or highly toxic raw materials, other special materials or materials transferred to another unit within the company's control do not need to be tested if the manufacturer's certificate of analysis is obtained, showing that these raw materials conform to established specifications. Visual examination of containers, labels and recording of batch numbers should help in establishing the identity of these materials. The lack of on-site testing for these materials should be justified and documented.

7.33 Samples should be representative of the batch of material from which they are taken. Sampling methods should specify the number of containers to be sampled, which part of the container to sample, and the amount of material to be taken from each container. The decision on the number of containers to sample and the sample size should be based upon a sampling plan that takes into consideration the criticality of the material, variability of the material, past quality history of the supplier and the quantity needed for analysis.

7.34 Sampling should be conducted at defined locations and by procedures designed to prevent contamination of the material sampled and contamination of other materials.

7.35 Containers from which samples are withdrawn should be opened carefully and subsequently reclosed. They should be marked to indicate that a sample has been taken.

7.4 **Storage**

7.40 Materials should be handled and stored in such a manner as to prevent degradation, contamination and cross-contamination.

7.41 Materials stored in fibre drums, bags or boxes should be stored off the floor and, when appropriate, suitably spaced to permit cleaning and inspection.

7.42 Materials should be stored under conditions and for a period that will have no adverse affect on their quality and should normally be controlled so that the oldest stock is used first.

7.43 Certain materials in suitable containers can be stored outdoors, provided identifying labels remain legible and containers are appropriately cleaned before opening and use.

7.44 Rejected materials should be identified and controlled under a quarantine system designed to prevent their unauthorized use in manufacturing.

7.5 Re-evaluation

7.50 Materials should be re-evaluated as appropriate to determine their suitability for use (e.g. after prolonged storage or exposure to heat or humidity).

8. Production and in-process controls

8.1 Production operations

8.10 Raw materials for manufacturing of intermediates and APIs should be weighed or measured under appropriate conditions that do not affect their suitability for use. Weighing and measuring devices should be of suitable accuracy for the intended use.

8.11 If a material is subdivided for later use in production operations, the container receiving the material should be suitable and should be so identified that the following information is available:

- material name and/or item code;
- receiving or control number;
- weight or measure of material in the new container; and
- re-evaluation or retest date if appropriate.

8.12 Critical weighing, measuring or subdividing operations should be witnessed or subjected to an equivalent control. Prior to use, production personnel should verify that the materials are those specified in the batch record for the intended intermediate or API.

8.13 Other critical activities should be witnessed or subjected to an equivalent control.

8.14 Actual yields should be compared with expected yields at designated steps in the production process. Expected yields with appropriate ranges should be established based on previous laboratory, pilot scale or manufacturing data. Deviations in yield associated with critical process steps should be investigated to determine their impact or potential impact on the resulting quality of affected batches.

8.15 Any deviation should be documented and explained. Any critical deviation should be investigated.

8.16 The processing status of major units of equipment should be indicated either on the individual units of equipment or by appropriate documentation, computer control systems or alternative means.

8.17 Materials to be reprocessed or reworked should be appropriately controlled to prevent unauthorized use.

8.2 Time limits

8.20 If time limits are specified in the master production instruction (see section 6.41), these time limits should be met to ensure the quality of intermediates and APIs. Deviations should be documented and evaluated. Time limits may be inappropriate when processing to a target value (e.g. pH adjustment, hydrogenation or drying to a predetermined specification) because completion of reactions or processing steps are determined by in-process sampling and testing.

8.21 Intermediates held for further processing should be stored under appropriate conditions to ensure their suitability for use.

8.3 In-process sampling and controls

8.30 Written procedures should be established to monitor the progress and control the performance of processing steps that cause variability in the quality characteristics of intermediates and APIs. In-process controls and their acceptance criteria should be defined based on the information gained during the development stage or historical data.

8.31 The acceptance criteria and type and extent of testing can depend on the nature of the intermediate or API being manufactured, the reaction or process step being conducted and the degree to which the process introduces variability in the product's quality. Less stringent in-process controls may be appropriate in early processing steps, whereas tighter controls may be appropriate for later processing steps (e.g. isolation and purification steps).

8.32 Critical in-process controls (and critical process monitoring), including the control points and methods, should be stated in writing and approved by the quality unit(s).

8.33 In-process controls can be performed by qualified production department personnel and the process adjusted without prior quality unit(s)' approval if the adjustments are made within pre-established limits approved by the quality unit(s). All tests and results should be fully documented as part of the batch record.

8.34 Written procedures should describe the sampling methods for in-process materials, intermediates and APIs. Sampling plans and procedures should be based on scientifically sound sampling practices.

8.35 In-process sampling should be conducted using procedures designed to prevent contamination of the sampled material and other intermediates or

APIs. Procedures should be established to ensure the integrity of samples after collection.

8.36 OOS investigations are not normally needed for in-process tests that are performed for the purpose of monitoring and/or adjusting the process.

8.4 **Blending batches of intermediates or APIs**

8.40 For the purpose of this document, blending is defined as the process of combining materials within the same specification to produce a homogeneous intermediate or API. In-process mixing of fractions from single batches (e.g. collecting several centrifuge loads from a single crystallization batch) or combining fractions from several batches for further processing is considered to be part of the production process and is not considered to be blending.

8.41 OOS batches should not be blended with other batches for the purpose of meeting specifications. Each batch incorporated into the blend should have been manufactured using an established process and should have been individually tested and found to meet appropriate specifications prior to blending.

8.42 Acceptable blending operations include but are not limited to:

- blending of small batches to increase batch size;
- blending of tailings (i.e. relatively small quantities of isolated material) from batches of the same intermediate or API to form a single batch.

8.43 Blending processes should be adequately controlled and documented and the blended batch should be tested for conformance to established specifications where appropriate.

8.44 The batch record of the blending process should allow traceability back to the individual batches that make up the blend.

8.45 Where physical attributes of the API are critical (e.g. APIs intended for use in solid oral dosage forms or suspensions), blending operations should be validated to show homogeneity of the combined batch. Validation should include testing of critical attributes (e.g. particle size distribution, bulk density and tap density) that may be affected by the blending process.

8.46 If the blending could adversely affect stability, stability testing of the final blended batches should be performed.

8.47 The expiry or retest date of the blended batch should be based on the manufacturing date of the oldest tailings or batch in the blend.

8.5 Contamination control

8.50 Residual materials can be carried over into successive batches of the same intermediate or API if there is adequate control. Examples include residue adhering to the wall of a micronizer, residual layer of damp crystals remaining in a centrifuge bowl after discharge and incomplete discharge of fluids or crystals from a processing vessel upon transfer of the material to the next step in the process. Such carry-over should not result in the carry-over of degradants or microbial contamination that may adversely alter the established impurity profile of the API.

8.51 Production operations should be conducted in a manner that will prevent contamination of intermediates or APIs by other materials.

8.52 Precautions to avoid contamination should be taken when APIs are handled after purification.

9. Packaging and identification labelling of APIs and intermediates

9.1 General

9.10 There should be written procedures describing the receipt, identification, quarantine, sampling, examination and/or testing and release and handling of packaging and labelling materials.

9.11 Packaging and labelling materials should conform to established specifications. Those that do not comply with such specifications should be rejected to prevent their use in operations for which they are unsuitable.

9.12 Records should be maintained for each shipment of labels and packaging materials showing receipt, examination, or testing and whether they are accepted or rejected.

9.2 Packaging materials

9.20 Containers should provide adequate protection against deterioration or contamination of the intermediate or API that may occur during transportation and recommended storage.

9.21 Containers should be clean and, where indicated by the nature of the intermediate or API, sanitized to ensure that they are suitable for their intended use. These containers should not be reactive, additive or absorptive to ensure that they do not alter the quality of the intermediate or API beyond the specified limits.

9.22 If containers are reused, they should be cleaned in accordance with documented procedures and all previous labels should be removed or defaced.

9.3 Label issuance and control

9.30 Access to the label storage areas should be limited to authorized personnel.

9.31 Procedures should be used to reconcile the quantities of labels issued, used and returned and to evaluate discrepancies found between the number of containers labelled and the number of labels issued. Such discrepancies should be investigated and the investigation should be approved by the quality unit(s).

9.32 All excess labels bearing batch numbers or other batch-related printing should be destroyed. Returned labels should be retained and stored in a manner that prevents mix-ups and provides proper identification.

9.33 Obsolete and outdated labels should be destroyed.

9.34 Printing devices used to print labels for packaging operations should be controlled to ensure that all imprinting conforms to the print specified in the batch production record.

9.35 Printed labels issued for a batch should be carefully examined for proper identity and conformity to specifications in the master production record. The results of this examination should be documented.

9.36 A printed label representative of those used should be included in the batch production record.

9.4 Packaging and labelling operations

9.40 There should be documented procedures designed to ensure that the correct packaging materials and labels are used.

9.41 Labelling operations should be designed to prevent mix-ups. They should be physically or spatially separated from operations involving other intermediates or APIs.

9.42 Labels used on containers of intermediates or APIs should indicate the name or identifying code, the batch number of the product and the storage conditions, when such information is critical to assure the quality of the intermediate or API.

9.43 If the intermediate or API is intended to be transferred outside the control of the manufacturer's material management system, the name and address of the manufacturer, quantity of contents and special transport conditions and any special legal requirements should also be included on the label. For intermediates or APIs with an expiry date, this date should be indicated on the label and certificate of analysis. For intermediates or APIs with a retest date, the retest date should be indicated on the label and/or certificate of analysis.

9.44 Packaging and labelling facilities should be inspected immediately before use to ensure that all materials not needed for the next packaging operation have been removed. This examination should be documented in the batch production records, the facility log or other documentation system.

9.45 Packaged and labelled intermediates or APIs should be examined to ensure that containers and packages in the batch have the correct label. This examination should be part of the packaging operation. Results of these examinations should be recorded in the batch production or control records.

9.46 Intermediate or API containers that are transported outside the manufacturer's control should be sealed in a manner such that, if the seal is breached or missing, the recipient will be alerted to the possibility that the contents may have been altered.

10. **Storage and distribution**

10.1 **Warehousing procedures**

10.10 Facilities should be available for the storage of all materials under appropriate conditions (e.g. controlled temperature and humidity when necessary). Records should be maintained of these conditions if they are critical for the maintenance of material characteristics.

10.11 Unless there is an alternative system to prevent the unintentional or unauthorized use of quarantined, rejected, returned or recalled materials, separate storage areas should be assigned for their temporary storage until the decision as to their future use has been taken.

10.2 **Distribution procedures**

10.20 APIs and intermediates should only be released for distribution to third parties after they have been released by the quality unit(s). APIs and intermediates can be transferred under quarantine to another unit under the company's control when authorized by the quality unit(s) and if appropriate controls and documentation are in place.

10.21 APIs and intermediates should be transported in a manner that does not adversely affect their quality.

10.22 Special transport or storage conditions for an API or intermediate should be stated on the label.

10.23 The manufacturer should ensure that the contract acceptor (contractor) for transportation of the API or intermediate knows and follows the appropriate transport and storage conditions.

10.24 A system should be in place by which the distribution of each batch of intermediate and/or API can be readily determined to permit its recall.

11. **Laboratory controls**

11.1 **General controls**

11.10 The independent quality unit(s) should have at its disposal adequate laboratory facilities.

11.11 There should be documented procedures describing sampling, testing, approval or rejection of materials and recording and storage of laboratory data. Laboratory records should be maintained in accordance with section 6.6.

11.12 All specifications, sampling plans and test procedures should be scientifically sound and appropriate to ensure that raw materials, intermediates, APIs, labels and packaging materials conform to established standards of quality and/or purity. Specifications and test procedures should be consistent with those included in the registration/filing. There can be specifications in addition to those in the registration/filing. Specifications, sampling plans and test procedures, including changes to them, should be drafted by the appropriate organizational unit and reviewed and approved by the quality unit(s).

11.13 Appropriate specifications should be established for APIs in accordance with accepted standards and be consistent with the manufacturing process. The specifications should include a control of the impurities (e.g. organic impurities, inorganic impurities and residual solvents). If the API has a specification for microbiological purity, appropriate action limits for total microbial counts and objectionable organisms should be established and met. If the API has a specification for endotoxins, appropriate action limits should be established and met.

11.14 Laboratory controls should be followed and documented at the time of performance. Any departures from the above-described procedures should be documented and explained.

11.15 Any OOS result obtained should be investigated and documented according to a procedure. This procedure should require analysis of the data, assessment of whether a significant problem exists, allocation of the tasks for corrective actions and conclusions. Any resampling and/or retesting after OOS results should be performed according to a documented procedure.

11.16 Reagents and standard solutions should be prepared and labelled following written procedures. "Use by" dates should be applied as appropriate for analytical reagents or standard solutions.

11.17 Primary reference standards should be obtained as appropriate for the manufacture of APIs. The source of each primary reference standard should be documented. Records should be maintained of each primary reference standard's storage and use in accordance with the supplier's recommendations. Primary reference standards obtained from an officially recognized source are normally used without testing if stored under conditions consistent with the supplier's recommendations.

11.18 Where a primary reference standard is not available from an officially recognized source, an "in-house primary standard" should be established. Appropriate testing should be performed to establish fully the identity and purity of the primary reference standard. Appropriate documentation of this testing should be maintained.

11.19 Secondary reference standards should be appropriately prepared, identified, tested, approved and stored. The suitability of each batch of secondary reference standard should be determined prior to first use by comparing against a primary reference standard. Each batch of secondary reference standard should be periodically requalified in accordance with a written protocol.

11.2 Testing of intermediates and APIs

11.20 For each batch of intermediate and API, appropriate laboratory tests should be conducted to determine conformance to specifications.

11.21 An impurity profile describing the identified and unidentified impurities present in a typical batch produced by a specific controlled production process should normally be established for each API. The impurity profile should include the identity or some qualitative analytical designation (e.g. retention time), the range of each impurity observed and classification of each identified impurity (e.g. inorganic, organic or solvent). The impurity profile is normally dependent upon the production process and origin of the API. Impurity profiles are normally not necessary for APIs of herbal or animal tissue origin. Biotechnology considerations are covered in ICH Guideline Q6B (1).

11.22 The impurity profile should be compared at appropriate intervals with the impurity profile in the regulatory submission or compared with historical data in order to detect changes to the API resulting from modifications to raw materials, equipment operating parameters or the production process.

11.23 Appropriate microbiological tests should be conducted on each batch of intermediate and API where microbial quality is specified.

11.3 **Validation of analytical procedures**

See section 12.

11.4 **Certificates of analysis**

11.40 Authentic certificates of analysis should be issued for each batch of intermediate or API on request.

11.41 Information on the name of the intermediate or API, including where appropriate its grade, the batch number and the date of release, should be provided on the certificate of analysis. For intermediates or APIs with an expiry date, the expiry date should be provided on the label and certificate of analysis. For intermediates or APIs with a retest date, the retest date should be indicated on the label and/or certificate of analysis.

11.42 The certificate should list each test performed in accordance with compendial or customer requirements, including the acceptance limits and the numerical results obtained (if test results are numerical).

11.43 Certificates should be dated and signed by authorized personnel from the quality unit(s) and should show the name, address and telephone number of the original manufacturer. Where the analysis has been carried out by a repacker or reprocessor, the certificate of analysis should show the name, address and telephone number of the repacker or reprocessor and a reference to the name of the original manufacturer.

11.44 If new certificates are issued by or on behalf of repackers or reproducers, agents or brokers, these certificates should show the name, address and telephone number of the laboratory that performed the analysis. They should also contain a reference to the name and address of the original manufacturer and to the original batch certificate, a copy of which should be attached.

11.5 **Stability monitoring of APIs**

11.50 A documented, ongoing testing programme should be designed to monitor the stability characteristics of APIs and the results should be used to confirm appropriate storage conditions and retest or expiry dates.

11.51 The test procedures used in stability testing should be validated and be stability-indicating.

11.52 Stability samples should be stored in containers that simulate the market container. For example, if the API is marketed in bags within fibre drums, stability samples can be packaged in bags of the same material and in smaller drums of similar or identical material composition to the drums in which the API is marketed.

11.53 Normally the first three commercial production batches should be placed on the stability monitoring programme to confirm the retest or expiry date. However, where data from previous studies show that the API is expected to remain stable for at least two years, fewer than three batches can be used.

11.54 Thereafter at least one batch per year of API manufactured (unless none is produced that year) should be added to the stability monitoring programme and tested at least annually to confirm the stability.

11.55 For APIs with short shelf-lives, testing should be done more frequently. For example, for those biotechnological/biological and other APIs with shelf-lives of one year or less, stability samples should be obtained and should be tested monthly for the first three months, and at three-monthly intervals after that. When data exist that confirm that the stability of the API is not compromised, elimination of specific test intervals (e.g. nine-month testing) can be considered.

11.56 Where appropriate, the stability storage conditions should be consistent with the WHO guidelines on stability.

11.6 Expiry and retest dating

11.60 When an intermediate is intended to be transferred outside the control of the manufacturer's material management system and an expiry or retest date is assigned, supporting stability information should be available (e.g. published data and test results).

11.61 An API expiry or retest date should be based on an evaluation of data derived from stability studies. Common practice is to use a retest date, not an expiration date.

11.62 Preliminary API expiry or retest dates can be based on pilot-scale batches if:

- the pilot batches employ a method of manufacture and a procedure that simulates the final process to be used on a commercial manufacturing scale; and
- the quality of the API represents the material to be made on a commercial scale.

11.63 A representative sample should be taken for the purpose of performing a retest.

11.7 Reserve/retention samples

11.70 The packaging and holding of reserve samples is for the purpose of potential future evaluation of the quality of batches of API and not for future stability testing.

11.71 Appropriately identified reserve samples of each batch of API should be retained for one year after the expiry date assigned by the manufacturer to the batch, or for three years after distribution of the batch, whichever is the longer. For APIs with retest dates, similar reserve samples should be retained for three years after the batch has been completely distributed by the manufacturer.

11.72 The reserve sample should be stored in the same packaging system in which the API is stored or in one that is equivalent to or more protective than the marketed packaging system. Sufficient quantities should be retained to conduct at least two full compendial analyses or, when there is no pharmacopoeial monograph, two full specification analyses.

12. **Validation**

12.1 **Validation policy**

12.10 The company's overall policy, intentions and approach to validation, including the validation of production processes, cleaning procedures, analytical methods, in-process control test procedures, computerized systems and personnel responsible for design, review, approval and documentation of each validation phase, should be documented.

12.11 The critical parameters and attributes should normally be identified during the development stage or from historical data and the ranges necessary for the reproducible operation should be defined. This should include:

- defining the API in terms of its critical product attributes;
- identifying process parameters that could affect the critical quality attributes of the API;
- determining the range for each critical process parameter expected to be used during routine manufacturing and process control.

12.12 Validation should extend to those operations determined to be critical to the quality and purity of the API.

12.2 **Validation documentation**

12.20 A written validation protocol should be established that specifies how validation of a particular process will be conducted. The protocol should be reviewed and approved by the quality unit(s) and other designated units.

12.21 The validation protocol should specify critical process steps and acceptance criteria as well as the type of validation to be conducted (e.g. retrospective, prospective or concurrent) and the number of process runs.

12.22 A validation report that cross-references the validation protocol should be prepared, summarizing the results obtained, commenting on any deviations observed and drawing the appropriate conclusions, including recommending changes to correct deficiencies.

12.23 Any variations from the validation protocol should be documented with appropriate justification.

12.3 Qualification

12.30 Before starting process validation activities, appropriate qualification of critical equipment and ancillary systems should be completed. Qualification is usually carried out by conducting the following activities, individually or combined:

- design qualification (DQ): documented verification that the proposed design of the facilities, equipment, or systems is suitable for the intended purpose;
- installation qualification (IQ): documented verification that the equipment or systems, as installed or modified, comply with the approved design, the manufacturer's recommendations and/or user requirements;
- operational qualification (OQ): documented verification that the equipment or systems, as installed or modified, perform as intended throughout the anticipated operating ranges;
- performance qualification (PQ): documented verification that the equipment and ancillary systems, as connected together, can perform effectively and reproducibly based on the approved process method and specifications.

12.4 Approaches to process validation

12.40 Process validation (PV) is the documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce an intermediate or API meeting its predetermined specifications and quality attributes.

12.41 There are three approaches to validation. Prospective validation is the preferred approach, but there are exceptions where the other approaches can be used. These three approaches and their applicability are outlined below.

12.42 Prospective validation should normally be performed for all API processes as defined in section 12.1.3. Prospective validation performed on an API process should be completed before the commercial distribution of the FPP manufactured from that API.

12.43 Concurrent validation can be conducted when data from replicate production runs are unavailable because only a limited number of API

batches have been produced, API batches are produced infrequently, or API batches are produced by a validated process that has been modified. Prior to the completion of concurrent validation, batches can be released and used in FPPs for commercial distribution based on thorough monitoring and testing of the API batches.

12.44 An exception can be made for retrospective validation for well-established processes that have been used without significant changes to API quality due to changes in raw materials, equipment, systems, facilities or the production process. This validation approach may be used where:

- (1) Critical quality attributes and critical process parameters have been identified.
- (2) Appropriate in-process acceptance criteria and controls have been established.
- (3) There have not been significant process or product failures attributable to causes other than operator error or equipment failures unrelated to equipment suitability.
- (4) Impurity profiles have been established for the existing API.

12.45 Batches selected for retrospective validation should be representative of all batches made during the review period, including any batches that failed to meet specifications, and should be sufficient in number to demonstrate process consistency. Retained samples can be tested to obtain data to retrospectively validate the process.

12.5 Process validation programme

12.50 The number of process runs for validation should depend on the complexity of the process or the magnitude of the process change being considered. For prospective and concurrent validation, three consecutive successful production batches should be used as a guide, but there may be situations where additional process runs are warranted to prove consistency of the process (e.g. complex API processes or API processes with prolonged completion times). Generally, for retrospective validation, data from 10 to 30 consecutive batches should be examined to assess process consistency, but fewer batches can be examined if justified.

12.51 Critical process parameters should be controlled and monitored during process validation studies. Process parameters unrelated to quality, such as variables controlled to minimize energy consumption or equipment use, need not be included in the process validation.

12.52 Process validation should confirm that the impurity profile for each API is within the limits specified. The impurity profile should be comparable to or better than historical data and, where applicable, the profile determined

during process development or for batches used for pivotal clinical and toxicological studies.

12.6 Periodic review of validated systems

12.60 Systems and processes should be periodically evaluated to verify that they are still operating in a valid manner. Where no significant changes have been made to the system or process, and a quality review confirms that the system or process is consistently producing material meeting its specifications, there is normally no need for revalidation.

12.7 Cleaning validation

12.70 Cleaning procedures should normally be validated. In general cleaning validation should be directed to those situations or process steps where contamination or carry-over of materials poses the greatest risk to API quality. For example, in early production it may be unnecessary to validate equipment cleaning procedures where residues are removed by subsequent purification steps.

12.71 Validation of cleaning procedures should reflect actual equipment usage patterns. If various APIs or intermediates are manufactured in the same equipment and the equipment is cleaned by the same process, a representative intermediate or API can be selected for cleaning validation. This selection should be based on the solubility and difficulty of cleaning and the calculation of residue limits based on potency, toxicity and stability.

12.72 The cleaning validation protocol should describe the equipment to be cleaned, procedures, materials, acceptable cleaning levels, parameters to be monitored and controlled and analytical methods. The protocol should also indicate the type of samples to be obtained and how they are collected and labelled.

12.73 Sampling should include swabbing, rinsing or alternative methods (e.g. direct extraction), as appropriate, to detect both insoluble and soluble residues. The sampling methods used should be capable of quantitatively measuring levels of residues remaining on the equipment surfaces after cleaning. Swab sampling may be impractical when product contact surfaces are not easily accessible due to equipment design and/or process limitations (e.g. inner surfaces of hoses, transfer pipes, reactor tanks with small ports for handling toxic materials and small intricate equipment such as micronizers and microfluidizers).

12.74 Validated analytical methods with the sensitivity to detect residues or contaminants should be used. The detection limit for each analytical method should be sufficiently sensitive to detect the established acceptable

level of the residue or contaminant. The method's attainable recovery level should be established. Residue limits should be practical, achievable and verifiable and be based on the most deleterious residue. Limits can be established based on the minimum known pharmacological, toxicological or physiological activity of the API or its most deleterious component.

12.75 Equipment cleaning or sanitization studies should address microbiological and endotoxin contamination for those processes where there is a need to reduce total microbiological count or endotoxins in the API, or other processes where such contamination could be of concern (e.g. non-sterile APIs used to manufacture sterile products).

12.76 Cleaning procedures should be monitored at appropriate intervals after validation to ensure that these procedures are effective when used during routine production. Equipment cleanliness can be monitored by analytical testing and visual examination, where feasible. Visual inspection can allow detection of gross contamination concentrated in small areas that could otherwise remain undetected by sampling and/or analysis.

12.8 **Validation of analytical methods**

12.80 Analytical methods should be validated unless the method employed is included in the relevant pharmacopoeia or other recognized standard reference. The suitability of all testing methods used should nonetheless be verified under actual conditions of use and documented.

12.81 Methods should be validated to include consideration of characteristics included within the ICH guidelines on validation of analytical methods. The degree of analytical validation performed should reflect the purpose of the analysis and the stage of the API production process.

12.82 Appropriate qualification of analytical equipment should be considered before starting validation of analytical methods.

12.83 Complete records should be maintained of any modification of a validated analytical method. Such records should include the reason for the modification and appropriate data to verify that the modification produces results that are as accurate and reliable as the established method.

13. **Change control**

13.10 A formal change control system should be established to evaluate all changes that may affect the production and control of the intermediate or API.

13.11 Written procedures should cover the identification, documentation, appropriate review, and approval of changes in raw materials, specifications,

analytical methods, facilities, support systems, equipment (including computer hardware), processing steps, labelling and packaging materials and computer software.

13.12 Any proposals for relevant changes to GMP should be drafted, reviewed and approved by the appropriate organizational units and reviewed and approved by the quality unit(s).

13.13 The potential impact of the proposed change on the quality of the intermediate or API should be evaluated. A classification procedure may help in determining the level of testing, validation and documentation needed to justify changes to a validated process. Changes can be classified (e.g. as minor or major) depending on their nature and extent and the effects these changes may have on the process. Scientific judgement should be used to determine what additional testing and validation studies are appropriate to justify a change in a validated process.

13.14 When implementing approved changes, measures should be taken to ensure that all documents affected by the changes are revised.

13.15 After the change has been implemented there should be an evaluation of the first batches produced or tested under the change.

13.16 The potential for critical changes to affect established retest or expiry dates should be evaluated. If necessary, samples of the intermediate or API produced by the modified process can be placed on an accelerated stability programme and/or can be added to the stability monitoring programme.

13.17 Manufacturers of the current dosage form should be notified of changes from established production and process control procedures that can impact the quality of the API.

14. **Rejection and reuse of materials**

14.1 **Rejection**

14.10 Intermediates and APIs failing to meet established specifications should be identified as such and quarantined. These intermediates or APIs can be reprocessed or reworked as described below. The final disposition of rejected materials should be recorded.

14.2 **Reprocessing**

14.20 Introducing an intermediate or API, including one that does not conform to standards or specifications, back into the process and reprocessing by repeating a crystallization step or other appropriate chemical or physical manipulation steps (e.g. distillation, filtration,

chromatography, milling) that are part of the established manufacturing process is generally considered acceptable. However, if such reprocessing is used for a majority of batches it should be included as part of the standard manufacturing process.

14.21 Continuation of a process step after an in-process control test has shown that the step is incomplete is considered to be part of the normal process. This is not considered to be reprocessing.

14.22 Introducing unreacted material back into a process and repeating a chemical reaction is considered to be reprocessing unless it is part of the established process. Such reprocessing should be preceded by careful evaluation to ensure that the quality of the intermediate or API is not adversely affected due to the potential formation of by-products and overreacted materials.

14.3 Reworking

14.30 Before a decision is taken to rework batches that do not conform to established standards or specifications, an investigation into the reason for non-conformance should be performed.

14.31 Batches that have been reworked should be subjected to appropriate evaluation, testing, stability testing if warranted and documentation to show that the reworked product is of equivalent quality to that produced by the original process. Concurrent validation is often the appropriate validation approach for rework procedures. This allows a protocol to define the rework procedure, how it will be carried out and the expected results. If there is only one batch to be reworked, then a report can be written and the batch released once it is found to be acceptable.

14.32 Procedures should provide for comparing the impurity profile of each reworked batch with batches manufactured by the established process. Where routine analytical methods are inadequate to characterize the reworked batch, additional methods should be used.

14.4 Recovery of materials and solvents

14.40 Recovery (e.g. from mother liquor or filtrates) of reactants, intermediates or the API is considered acceptable, provided that approved procedures exist for the recovery and the recovered materials meet specifications suitable for their intended use.

14.41 Solvents can be recovered and reused in the same processes or in different processes, provided that the recovery procedures are controlled and monitored to ensure that solvents meet appropriate standards before reuse or comingling with other approved materials.

14.42 Fresh and recovered solvents and reagents can be combined if adequate testing has shown their suitability for all manufacturing processes in which they may be used.

14.43 The use of recovered solvents, mother liquors and other recovered materials should be adequately documented.

14.5 Returns

14.50 Returned intermediates or APIs should be identified as such and quarantined.

14.51 If the conditions under which returned intermediates or APIs have been stored or shipped before or during their return, or the condition of their containers casts doubt on their quality, the returned intermediates or APIs should be reprocessed, reworked or destroyed, as appropriate.

14.52 Records of returned intermediates or APIs should be maintained. For each return, documentation should include:

- name and address of the consignee;
- intermediate or API, batch number and quantity returned;
- reason for return; and
- use or disposal of the returned intermediate or API.

15. Complaints and recalls

15.10 All quality-related complaints, whether received orally or in writing, should be recorded and investigated according to a written procedure.

15.11 Complaint records should include:

- name and address of complainant;
- name (and, where appropriate, title) and telephone number of person submitting the complaint;
- nature of the complaint (including name and batch number of the API);
- date the complaint was received;
- action initially taken (including dates and identity of person taking the action);
- any follow-up action taken;
- response provided to the originator of complaint (including date on which the response was sent); and
- final decision on intermediate or API batch or lot.

15.12 Records of complaints should be retained in order to evaluate trends, product-related frequencies and severity with a view to taking additional, and if appropriate, immediate corrective action.

15.13 There should be a written procedure that defines the circumstances under which a recall of an intermediate or API should be considered.

15.14 The recall procedure should designate who should be involved in evaluating the information, how a recall should be initiated, who should be informed about the recall and how the recalled material should be treated.

15.15 In the event of a serious or potentially life-threatening situation, local, national and/or international authorities should be informed and their advice sought.

16. **Contract manufacturers (including laboratories)**

16.10 All contract manufacturers (including laboratories) should comply with GMP defined in this guide. Special consideration should be given to the prevention of cross-contamination and to maintaining traceability.

16.11 Contract manufacturers (including laboratories) should be evaluated by the contract giver to ensure GMP compliance of the specific operations taking place at the contract sites.

16.12 There should be a written and approved contract or formal agreement between the contract giver and the contract acceptor that defines in detail the GMP responsibilities, including the quality measures, of each party.

16.13 The contract should permit the contract giver to audit the contract acceptor's facilities for compliance with GMP.

16.14 Where subcontracting is allowed the contract acceptor should not pass to a third party any of the work entrusted to him or her under the contract without the contract giver's prior evaluation and approval of the arrangements.

16.15 Manufacturing and laboratory records should be kept at the site where the activity takes place and be readily available.

16.16 Changes in the process, equipment, test methods, specifications or other contractual requirements should not be made unless the contract giver is informed and approves the changes.

17. **Agents, brokers, traders, distributors, repackers and relabellers**

17.1 **Applicability**

17.10 This section applies to any party other than the original manufacturer who may trade and/or take possession of, repack, relabel, manipulate, distribute or store an API or intermediate.

17.11 All agents, brokers, traders, distributors, repackers and relabellers should comply with GMP as defined in this guide.

17.2 Traceability of distributed APIs and intermediates

17.20 Agents, brokers, traders, distributors, repackers or relabellers should maintain complete traceability of the APIs and intermediates that they distribute. Documents that should be retained and available should include:

- identity of original manufacturer;
- address of original manufacturer;
- purchase orders;
- bills of lading (transportation documentation);
- receipt documents;
- name or designation of API or intermediate;
- manufacturer's batch number;
- transportation and distribution records;
- all authentic certificates of analysis, including those of the original manufacturer; and
- retest or expiry date.

17.3 Quality management

17.30 Agents, brokers, traders, distributors, repackers or relabellers should establish, document and implement an effective system of managing quality, as specified in section 2.

17.4 Repackaging, relabelling and holding of APIs and intermediates

17.40 Repackaging, relabelling and holding of APIs and intermediates should be performed under appropriate GMP controls as stipulated in this guide, to avoid mix-ups and loss of API or intermediate identity or purity.

17.41 Repackaging should be conducted under appropriate environmental conditions to avoid contamination and cross-contamination.

17.5 Stability

17.50 Stability studies to justify assigned expiration or retest dates should be conducted if the API or intermediate is repackaged in a different type of container than that used by the manufacturer of the API or intermediate.

17.6 Transfer of information

17.60 Agents, brokers, distributors, repackers or relabellers should transfer all quality or regulatory information received from the manufacturer

of an API or intermediate to the customer, and from the customer to the manufacturer of the API or intermediate.

17.61 The agent, broker, trader, distributor, repacker or relabeller who supplies the API or intermediate to the customer should provide the name of the original manufacturer of the API or intermediate and the batch number(s) supplied.

17.62 The agent should also provide the identity of the manufacturer of the original API or intermediate to regulatory authorities upon request. The original manufacturer can respond to the regulatory authority directly or through its authorized agents, depending on the legal relationship between the authorized agents and the original manufacturer of the API or intermediate. (In this context “authorized” refers to authorized by the manufacturer.)

17.63 The specific guidance for certificates of analysis included in section 11.4 should be met.

17.7 Handling of complaints and recalls

17.70 Agents, brokers, traders, distributors, repackers or relabellers should maintain records of complaints and recalls as specified in section 15 for all complaints and recalls that come to their attention.

17.71 If the situation warrants, the agents, brokers, traders, distributors, repackers or relabellers should review the complaint with the manufacturer of the original API or intermediate to determine whether any further action, either with other customers who may have received this API or intermediate or with the regulatory authority, or both, should be initiated. The investigation into the cause for the complaint or recall should be conducted and documented by the appropriate party.

17.72 Where a complaint is referred to the original manufacturer of the API or intermediate, the record maintained by the agents, brokers, traders, distributors, repackers or relabellers should include any response received from the original manufacturer of the API or intermediate (including date and information provided).

17.8 Handling of returns

17.80 Returns should be handled as specified in section 14.5.3. The agents, brokers, traders, distributors, repackers or relabellers should maintain documentation of returned APIs and intermediates.

18. **Specific guidance for APIs manufactured by cell culture/fermentation²**

18.1 **General**

18.10 Section 18 is intended to address specific controls for APIs or intermediates manufactured by cell culture or fermentation using natural or recombinant organisms and that have not been covered adequately in the previous sections. It is not intended to be a stand-alone section. In general, the GMP principles in the other sections of this document apply. Note that the principles of fermentation for “classical” processes for production of small molecules and for processes using recombinant and non-recombinant organisms for production of proteins and/or polypeptides are the same, although the degree of control will differ. Where practical, this section will address these differences. In general, the degree of control for biotechnological processes used to produce proteins and polypeptides is greater than that for classical fermentation processes.

18.11 The term “biotechnological process” (biotech) refers to the use of cells or organisms that have been generated or modified by recombinant DNA, hybridoma or other technology to produce APIs. The APIs produced by biotechnological processes normally consist of high molecular weight substances, such as proteins and polypeptides, for which specific guidance is given in this Section. Certain APIs of low molecular weight, such as antibiotics, amino acids, vitamins, and carbohydrates, can also be produced by recombinant DNA technology. The level of control for these types of APIs is similar to that employed for classical fermentation.

18.12 The term “classical fermentation” refers to processes that use microorganisms existing in nature and/or modified by conventional methods (e.g. irradiation or chemical mutagenesis) to produce APIs. APIs produced by “classical fermentation” are normally low molecular weight products such as antibiotics, amino acids, vitamins, and carbohydrates.

18.13 Production of APIs or intermediates from cell culture or fermentation involves biological processes such as cultivation of cells or extraction and purification of material from living organisms. Note that there may be additional process steps, such as physicochemical modification, that are part of the manufacturing process. The raw materials used (media, buffer components) may provide the potential for growth of microbiological contaminants. Depending on the source, method of preparation, and the intended use of the API or intermediate, control of bioburden, viral

² This section has been referred to the Expert Committee on Biological Standardization for discussion and consideration. Reproduced here but currently not adopted by the aforementioned Expert Committee.

contamination, and/or endotoxins during manufacturing and monitoring of the process at appropriate stages may be necessary.

18.14 Appropriate controls should be established at all stages of manufacturing to assure intermediate and/or API quality. While this guide starts at the cell culture/fermentation step, prior steps (e.g. cell banking) should be performed under appropriate process controls. This guide covers cell culture/fermentation from the point at which a vial of the cell bank is retrieved for use in manufacturing.

18.15 Appropriate equipment and environmental controls should be used to minimize the risk of contamination. The acceptance criteria for quality of the environment and the frequency of monitoring should depend on the step in production and the production conditions (open, closed or contained systems).

18.16 In general, process controls should take into account:

- maintenance of the working cell bank (where appropriate);
- proper inoculation and expansion of the culture;
- control of the critical operating parameters during fermentation/cell culture;
- monitoring of the process for cell growth, viability (for most cell culture processes) and productivity where appropriate;
- harvest and purification procedures that remove cells, cellular debris and media components while protecting the intermediate or API from contamination (particularly of a microbiological nature) and from loss of quality;
- monitoring of bioburden and, where needed, endotoxin levels at appropriate stages of production; and
- viral safety concerns as described in ICH Guideline Q5A (2)..

18.17 Where appropriate, the removal of media components, host cell proteins, other process-related impurities, product-related impurities and contaminants should be demonstrated.

18.2 Cell bank maintenance and record keeping

18.20 Access to cell banks should be limited to authorized personnel.

18.21 Cell banks should be maintained under storage conditions designed to maintain viability and prevent contamination.

18.22 Records of the use of the vials from the cell banks and storage conditions should be maintained.

18.23 Where appropriate, cell banks should be periodically monitored to determine suitability for use.

18.24 See ICH Guideline Q5D (3) for a more complete discussion of cell banking.

18.3 Cell culture/fermentation

18.30 Where aseptic addition of cell substrates, media, buffers, and gases is needed, closed or contained systems should be used where possible. If the inoculation of the initial vessel or subsequent transfers or additions (media, buffers) are performed in open vessels, there should be controls and procedures in place to minimize the risk of contamination.

18.31 Where the quality of the API can be affected by microbial contamination, manipulations using open vessels should be performed in a biosafety cabinet or similarly controlled environment.

18.32 Personnel should be appropriately gowned and take special precautions handling the cultures.

18.33 Critical operating parameters (for example temperature, pH, agitation rates, addition of gases, pressure) should be monitored to ensure consistency with the established process. Cell growth, viability (for most cell culture processes), and, where appropriate, productivity should also be monitored. Critical parameters will vary from one process to another, and for classical fermentation, certain parameters (cell viability, for example) may not need to be monitored.

18.34 Cell culture equipment should be cleaned and sterilized after use. As appropriate, fermentation equipment should be cleaned, and sanitized or sterilized.

18.35 Culture media should be sterilized before use when appropriate to protect the quality of the API.

18.36 There should be appropriate procedures in place to detect contamination and determine the course of action to be taken. This should include procedures to determine the impact of the contamination on the product and those to decontaminate the equipment and return it to a condition to be used in subsequent batches. Foreign organisms observed during fermentation processes should be identified as appropriate and the effect of their presence on product quality should be assessed, if necessary. The results of such assessments should be taken into consideration in the disposition of the material produced.

18.37 Records of contamination events should be maintained.

18.38 Shared (multiproduct) equipment may warrant additional testing after cleaning between product campaigns, as appropriate, to minimize the risk of cross-contamination.

18.4 **Harvesting, isolation and purification**

18.40 Harvesting steps, either to remove cells or cellular components or to collect cellular components after disruption, should be performed in equipment and areas designed to minimize the risk of contamination.

18.41 Harvest and purification procedures that remove or inactivate the producing organism, cellular debris and media components (while minimizing degradation, contamination, and loss of quality) should be adequate to ensure that the intermediate or API is recovered with consistent quality.

18.42 All equipment should be properly cleaned and, as appropriate, sanitized after use. Multiple successive batching without cleaning can be used if intermediate or API quality is not compromised.

18.43 If open systems are used, purification should be performed under environmental conditions appropriate for the preservation of product quality.

18.44 Additional controls, such as the use of dedicated chromatography resins or additional testing, may be appropriate if equipment is to be used for multiple products.

18.5 **Viral removal/inactivation steps**

18.50 See the ICH Guideline Q5A (2) for more specific information.

18.51 Viral removal and viral inactivation steps are critical processing steps for some processes and should be performed within their validated parameters.

18.52 Appropriate precautions should be taken to prevent potential viral contamination from pre-viral to post-viral removal/inactivation steps. Therefore, open processing should be performed in areas that are separate from other processing activities and have separate air handling units.

18.53 The same equipment is not normally used for different purification steps. However, if the same equipment is to be used, the equipment should be appropriately cleaned and sanitized before reuse. Appropriate precautions should be taken to prevent potential virus carry-over (e.g. through equipment or environment) from previous steps.

19. **APIs for use in clinical trials**

19.1 **General**

19.10 Not all the controls in the previous sections of this guide are appropriate for the manufacture of a new API for investigational use during

its development. Section 19 provides specific guidance unique to these circumstances.

19.11 The controls used in the manufacture of APIs for use in clinical trials should be consistent with the stage of development of the pharmaceutical product incorporating the API. Process and test procedures should be flexible to allow for changes to be made as knowledge of the process increases and clinical testing of a pharmaceutical product progresses from the preclinical stages through the clinical stages. Once pharmaceutical development reaches the stage where the API is produced for use in pharmaceutical products intended for clinical trials, manufacturers should ensure that APIs are manufactured in suitable facilities using appropriate production and control procedures to ensure the quality of the API.

19.2 **Quality**

19.20 Appropriate GMP concepts should be applied in the production of APIs for use in clinical trials with a suitable mechanism for the approval of each batch.

19.21 A quality unit(s) independent from production should be established for the approval or rejection of each batch of API for use in clinical trials.

19.22 Some of the testing functions commonly performed by the quality unit(s) can be performed within other organizational units.

19.23 Quality measures should include a system for testing of raw materials, packaging materials, intermediates and APIs.

19.24 Process and quality problems should be evaluated.

19.25 Labelling for APIs intended for use in clinical trials should be appropriately controlled and should identify the material as being for investigational use.

19.3 **Equipment and facilities**

19.30 During all phases of clinical development, including the use of small-scale facilities or laboratories to manufacture batches of APIs for use in clinical trials, procedures should be in place to ensure that equipment is calibrated, clean and suitable for its intended use.

19.31 Procedures for the use of facilities should ensure that materials are handled in a manner that minimizes the risk of contamination and cross-contamination.

19.4 **Control of raw materials**

19.40 Raw materials used in production of APIs for use in clinical trials should be evaluated by testing or be received with a supplier's analysis and

subjected to identity testing. When a material is considered hazardous a supplier's analysis should suffice.

19.41 In some instances the suitability of a raw material can be determined before use based on acceptability in small-scale reactions (i.e. use testing) rather than on analytical testing alone.

19.5 **Production**

19.50 The production of APIs for use in clinical trials should be documented in laboratory notebooks, batch records or by other appropriate means. These documents should include information on the use of production materials, equipment, processing and scientific observations.

19.51 Expected yields can be more variable and less defined than the expected yields used in commercial processes. Investigations into yield variations are not expected.

19.6 **Validation**

19.60 Process validation for the production of APIs for use in clinical trials is normally inappropriate where a single API batch is produced or where process changes during development of an API make batch replication difficult or inexact. The combination of controls, calibration and, where appropriate, equipment qualification assures quality of the API during this development phase.

19.61 Process validation should be conducted in accordance with section 12 when batches are produced for commercial use, even when such batches are produced on a pilot scale or small scale.

19.7 **Changes**

19.70 Changes are expected during development as knowledge is gained and the production is scaled up. Every change in the production, specifications or test procedures should be adequately recorded.

19.8 **Laboratory controls**

19.80 While analytical methods performed to evaluate a batch of API for clinical trials may not yet be validated they should be scientifically sound.

19.81 A system for retaining reserve samples of all batches should be in place. This system should ensure that a sufficient quantity of each reserve sample is retained for an appropriate length of time after approval, termination or discontinuation of an application.

19.82 Expiry and retest dating as defined in section 11.6 applies to existing APIs used in clinical trials. For new APIs section 11.6 does not normally apply in early stages of clinical trials.

19.9 Documentation

19.90 A system should be in place to ensure that information gained during the development and the manufacture of APIs for use in clinical trials is documented and available.

19.91 The development and implementation of the analytical methods used to support the release of a batch of API for use in clinical trials should be appropriately documented.

19.92 A system for retaining production and control records and documents should be used. This system should ensure that records and documents are retained for an appropriate length of time after the approval, termination or discontinuation of an application.

20. Glossary

acceptance criteria

Numerical limits, ranges or other suitable measures for acceptance of test results.

active pharmaceutical ingredient (API) (or pharmaceutical substance)

Any substance or mixture of substances intended to be used in the manufacture of a finished pharmaceutical product (FPP) and that, when used in the production of a pharmaceutical product, becomes an active ingredient of the pharmaceutical product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body.

API starting material

A raw material, intermediate or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API starting material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement or produced in-house. API starting materials normally have defined chemical properties and structure.

batch (or lot)

A specific quantity of material produced in a process or series of processes so that it is expected to be homogeneous within specified limits. In the case

of continuous production, a batch may correspond to a defined fraction of the production. The batch size can be defined either by a fixed quantity or by the amount produced in a fixed time interval.

batch number (or lot number)

A unique combination of numbers, letters and/or symbols that identifies a batch (or lot) and from which the production and distribution history can be determined.

bioburden

The level and type (e.g. objectionable or not) of microorganisms that can be present in raw materials, API starting materials, intermediates or APIs. Bioburden should not be considered contamination unless the levels have been exceeded or defined objectionable organisms have been detected.

calibration

The demonstration that a particular instrument or device produces results within specified limits by comparison with those produced by a reference or traceable standard over an appropriate range of measurements.

computer system

A group of hardware components and associated software, designed and assembled to perform a specific function or group of functions.

computerized system

A process or operation integrated with a computer system.

contamination

The undesired introduction of impurities of a chemical or microbiological nature or of foreign matter into or on to a raw material, intermediate or API during production, sampling, packaging or repackaging, storage or transport.

contract manufacturer

A manufacturer performing some aspect of manufacturing on behalf of the original manufacturer.

critical

Describes a process step, process condition, test requirement or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the API meets its specification.

cross-contamination

Contamination of a material or product with another material or product.

deviation

Departure from an approved instruction or established standard.

expiry date (or expiration date)

The date placed on the container or labels of an API designating the time during which the API is expected to remain within established shelf-life specifications if stored under defined conditions and after which it should not be used.

finished pharmaceutical product (FPP)

ICH: The dosage form in the final immediate packaging intended for marketing (reference Q1A (4)).

WHO: A product that has undergone all stages of production, including packaging in its final container and labelling. An FPP may contain one or more APIs.

impurity

Any component present in the intermediate or API that is not the desired entity.

impurity profile

A description of the identified and unidentified impurities present in an API.

in-process control (or process control)

Checks performed during production in order to monitor and, if appropriate, to adjust the process and/or to ensure that the intermediate or API conforms to its specifications.

intermediate

A material produced during steps of the processing of an API that undergoes further molecular change or purification before it becomes an API. Intermediates may or may not be isolated.

(*Note:* this guide only addresses those intermediates produced after the point that the company has defined as the point at which the production of the API begins.)

lot

See Batch.

lot number

See Batch number.

manufacture

All operations of receipt of materials, production, packaging, repackaging, labelling, relabelling, quality control, release, storage and distribution of APIs and related controls.

material

A general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials.

mother liquor

The residual liquid which remains after the crystallization or isolation processes. A mother liquor may contain unreacted materials, intermediates, levels of the API and/or impurities. It may be used for further processing.

packaging material

Any material intended to protect an intermediate or API during storage and transport.

pharmaceutical substance

See Active pharmaceutical ingredient.

procedure

A documented description of the operations to be performed, the precautions to be taken and measures to be applied, directly or indirectly related to the manufacture of an intermediate or API.

process aids

Materials, excluding solvents, used as an aid in the manufacture of an intermediate or API that do not themselves participate in a chemical or biological reaction (e.g. filter aid or activated carbon).

process control

See In-process control.

production

All operations involved in the preparation of an API from receipt of materials through processing and packaging of the API.

qualification

Action of proving and documenting that equipment or ancillary systems are properly installed, work correctly and actually lead to the expected results. Qualification is part of validation, but the individual qualification steps alone do not constitute process validation.

quality assurance (QA)

The sum total of the organized arrangements made with the object of ensuring that all APIs are of the quality required for their intended use and that quality systems are maintained.

quality control (QC)

Checking or testing that specifications are met.

quality unit(s)

An organizational unit independent of production which fulfils both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.

quarantine

The status of materials isolated physically or by other effective means pending a decision on their subsequent approval or rejection.

raw material

A general term used to denote starting materials, reagents and solvents intended for use in the production of intermediates or APIs.

reference standard, primary

A substance that has been shown by an extensive set of analytical tests to be authentic material that should be of high purity. This standard can be:

- obtained from an officially recognized source;
- prepared by independent synthesis;
- obtained from existing production material of high purity; or
- prepared by further purification of existing production material.

reference standard, secondary

A substance of established quality and purity, as shown by comparison to a primary reference standard, used as a reference standard for routine laboratory analysis.

reprocessing

Introducing an intermediate or API, including one that does not conform to standards or specifications, back into the process and repeating a crystallization step or other appropriate chemical or physical manipulation steps (e.g. distillation, filtration, chromatography or milling) that are part of the established manufacturing process. Continuation of a process step after an in-process control test has shown that the step is incomplete is considered to be part of the normal process and not to be reprocessing.

retest date

The date when a material should be re-examined to ensure that it is still suitable for use.

reworking

Subjecting an intermediate or API that does not conform to standards or specifications to one or more processing steps that are different from the established manufacturing process to obtain acceptable quality intermediate or API (e.g. recrystallizing with a different solvent).

signature (signed)

See Signed.

signed (signature)

The record of the individual who performed a particular action or review. This record can be in the form of initials, full handwritten signature, personal seal or an authenticated and secure electronic signature.

solvent

An inorganic or organic liquid used as a vehicle for the preparation of solutions or suspensions in the manufacture of an intermediate or API.

specification

A list of tests, references to analytical procedures and appropriate acceptance criteria that are numerical limits, ranges or other criteria for the test described. It establishes the set of criteria to which a material should conform to be considered acceptable for its intended use. "Conformance to specification" means that the material, when tested according to the listed analytical procedures, will meet the listed acceptance criteria.

validation

A documented programme that provides a high degree of assurance that a specific process, method or system will consistently produce a result meeting predetermined acceptance criteria.

validation protocol

A written plan stating how validation will be conducted and defining acceptance criteria. For example, the protocol for a manufacturing process identifies processing equipment, critical process parameters and operating ranges, product characteristics, sampling, test data to be collected, number of validation runs and acceptable test results.

yield, expected

The quantity of material or the percentage of theoretical yield anticipated at any appropriate phase of production based on previous laboratory, pilot-scale or manufacturing data.

yield, theoretical

The quantity that would be produced at any appropriate phase of production, based upon the quantity of material to be used, in the absence of any loss or error in actual production.

References

1. *ICH Harmonised Tripartite Guideline: Specifications: test procedures and acceptance criteria for biotechnological/biological products Q6B*. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1999.
2. *ICH Harmonised Tripartite Guideline: Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A*. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1999.
3. *ICH Harmonised Tripartite Guideline: Derivation and characterisation of cell substrates used for production of biotechnological/biological products Q5D*. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1997.
4. *ICH Harmonised Tripartite Guideline: Stability testing of new drug substances and products Q1A*. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2003.

Appendix 1

List of references for related WHO guidelines

Distribution

(http://www.who.int/medicines/areas/quality_safety/quality_assurance/distribution/en/)

Good trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 2 (WHO Technical Report Series, No. 917).

WHO pharmaceutical starting materials certification scheme (SMACS): guidelines on implementation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 3 (WHO Technical Report Series, No. 917).

Guide to good storage practices for pharmaceuticals In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 9 (WHO Technical Report Series, No. 908).

Production

(http://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html)

Good Manufacturing Practices for Pharmaceutical Products: Main Principles. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 4 (WHO Technical Report Series, No. 908).

Good manufacturing practices: requirement for the sampling of starting materials (amendment). In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 2 (WHO Technical Report Series, No. 929).

Sterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 6 (WHO Technical Report Series, No. 902).

Investigational pharmaceutical products for clinical trials in humans. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations*.

Thirty-fourth report. Geneva, World Health Organization, 1996, Annex 7 (WHO Technical Report Series, No. 863).

Herbal medicinal products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report.* Geneva, World Health Organization, 2006, Annex 3 (WHO Technical Report Series, No. 937).

Water for pharmaceutical use. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report.* Geneva, World Health Organization, 2005, Annex 3 (WHO Technical Report Series, No. 929).

Heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report.* Geneva, World Health Organization, 2006, Annex 2 (WHO Technical Report Series, No. 937).

Validation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report.* Geneva, World Health Organization, 2006, Annex 4 (WHO Technical Report Series, No. 937).

Quality control

(http://www.who.int/medicines/areas/quality_safety/quality_assurance/control/en/index.html)

The International Pharmacopoeia (Ph. Int.) — Fourth Edition + First Supplement. Geneva, World Health Organization, 2006.

General guidelines for the establishment, maintenance and distribution of chemical reference substances. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report.* Geneva, World Health Organization, 2007, Annex 3 (WHO Technical Report Series, No. 943).

Considerations for requesting analyses of drug samples. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report.* Geneva, World Health Organization, 2002, Annex 4 (WHO Technical Report Series, No. 902).

Model certificate of analysis. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report.* Geneva, World Health Organization, 2002, Annex 10 (WHO Technical Report Series, No. 902).

Related regulatory standards

(http://www.who.int/medicines/areas/quality_safety/quality_assurance/regulatory_standards/en/)

Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 2 (WHO Technical Report Series, No. 953).

Procedure for assessing the acceptability, in principle, of active pharmaceutical ingredients for use in pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 4 (WHO Technical Report Series, No. 953).

Guidelines on active pharmaceutical ingredient master file procedure. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-second report*. Geneva, World Health Organization, 2008, Annex 4 (WHO Technical Report Series, No. 948).

Guidance on variations to a prequalified product dossier. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report*. Geneva, World Health Organization, 2007, Annex 6 (WHO Technical Report Series, No. 943).

WHO guidelines for sampling of pharmaceutical products and related materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 4 (WHO Technical Report Series, No. 929).

Appendix 2

General notes: additional clarifications and explanations

2.1.1 The intent of this clause is that senior management of the API manufacturer has the responsibility to ensure that there is an effective quality management system in place and that all employees are made aware of their roles and responsibilities in assuring the quality of the API(s) produced.

2.3 The intent of this clause is to specify the roles and responsibilities that should apply to production activities and, in particular, that these responsibilities should not be delegated to non-production personnel within the company or to any persons outside the company.

5.2.1 This clause requires a written standard operating procedure (SOP) covering the maintenance of equipment. Important information to specify in this SOP should include:

- who is responsible for coordinating equipment maintenance activities (usually production management or engineering management);
- a provision that a schedule of planned preventive maintenance of equipment should be available (a useful reference is *ISPE Good Practice Guide: Maintenance. May 2009*) (1);
- a statement of the necessity to follow proper change control procedures where non-routine repairs, or modifications, replacements or other activities, are required.

7.1.2 There is an expectation that suppliers of critical materials should be subject to on-site audits as part of the company's supplier qualification programme.

7.2.1 There is an expectation that upon receipt and before acceptance of materials, each container or grouping of containers of materials should be examined visually for correct labelling, including correlation between the name used by the supplier and the in-house name. If these names are different, both names should be recorded and verified against a previously approved list of synonyms and checked by a scientifically qualified person.

7.3.1 This clause requires that at least one test be performed to verify the identity of each batch of material received. For clarification, one test for identity may not be sufficient in the majority of cases as this is dependent on various aspects, including supplier qualification.

11.7.3 For clarification, the reserve sample should be stored in a packaging system designed to give maximum protection of the API against change over time, e.g. a glass bottle with tightly fitted cap.

17. Refer to WHO GTDP (2) and WHO GMP for excipients (3).
18. See footnote on p. 174.

API starting material

As discussed in this document the introduction of the API starting material into the manufacturing process is where the requirements of GMP commence.

The API starting material itself needs to be proposed and justified by the manufacturer and accepted as such by assessors. This justification should be documented and be available for review by WHO GMP inspectors.

The API starting material should be fully characterized according to identity and purity. In addition, the steps prior to the step where the API starting material appears, which may involve “starting materials for synthesis”, should be available in the form of a flow chart.

In general, the starting materials for synthesis should:

- be a synthetic precursor one or more synthetic steps prior to the final API intermediate;
- be a well characterized, isolated and purified substance with a fully elucidated structure;
- have well defined specifications which include one or more specific identity tests, and tests and limits for potency, specified and unspecified impurities and total impurities.

References

1. International Society for Pharmaceutical Engineering. *ISPE good practice guide: maintenance*. 2009 (http://www.ispe.org/cs/ispe_good_practice_guides_section/ispe_good_practice_guides).
2. Good trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 2 (WHO Technical Report Series, No. 917) (http://www.who.int/medicines/areas/quality_safety/quality_assurance/distribution/en/index.html).
3. WHO GMP for excipients In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report*. Geneva, World Health Organization, 1999, Annex 5 (WHO Technical Report Series, No. 885) (http://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html); and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2*, 2nd updated ed., *Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.